Masimo (NASDAQ:MASI) today announced the findings of a prospective study published in Pediatrics International in which Dr. Ya-Fei Liu and colleagues at Peking University First Hospital in Beijing evaluated the ability of noninvasive, continuous Masimo PVi®, alongside other dynamic parameters, to predict fluid responsiveness in children 1-3 years old who were undergoing major neurosurgery. The researchers concluded, “Volume-based PVi and ∆Vpeak [respiratory variation in aortic blood flow peak velocity] showed acceptable reliabilities for fluid responsiveness prediction in young children undergoing major neurosurgery, while pressure-based SVV [stroke volume variation] using FloTrac/Vigileo, Eadyn [dynamic arterial elastance], and PPV [pulse pressure variation] [did] not.”1
Cantor Fitzgerald Initiates Coverage On Intellia Therapeutics with Overweight Rating, Announces Price Target of $67
Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Overweight rating and announces Price Target of $67.